|
1
|
Arrese M, Cabrera D, Kalergis AM and
Feldstein AE: Innate immunity and inflammation in NAFLD/NASH. Dig
Dis Sci. 61:1294–1303. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tiniakos DG, Vos MB and Brunt EM:
Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu
Rev Pathol. 5:145–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang S, Rutkowsky JM, Snodgrass RG,
Ono-Moore KD, Schneider DA, Newman JW, Adams SH and Hwang DH:
Saturated fatty acids activate TLR-mediated proinflmmatory
signaling pathways. J Lipid Res. 53:2002–2013. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ganz M and Szabo G: Immune and
inflammatory pathways in NASH. Hepatol Int. 7(Suppl 2): S771–S781.
2013. View Article : Google Scholar
|
|
5
|
Petrasek J, Csak T and Szabo G: Toll-like
receptors in liver disease. Adv Clin Chem. 59:155–201. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bieghs V and Trautwein C: Innate immune
signaling and gut-liver interactions in non-alcoholic fatty liver
disease. Hepatobiliary Surg Nutr. 3:377–385. 2014.
|
|
7
|
Kiziltas S: Toll-like receptors in
pathophysiology of liver diseases. World J Hepatol. 8:1354–1369.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farrell GC, van Rooyen D, Gan L and
Chitturi S: NASH is an inflammatory disorder: Pathogenic,
prognostic and therapeutic implications. Gut Liver. 6:149–171.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Y, Tu Q, Yan W, Xiao D, Zeng Z,
Ouyang Y, Huang L, Cai J, Zeng X, Chen YJ and Liu A: CXC195
suppresses proliferation and inflammatory response in LPS-induced
human hepatocellular carcinoma cells via regulating
TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway. Biochem Biophys
Res Commun. 456:373–379. 2015. View Article : Google Scholar
|
|
10
|
Venkatesha SH, Astry B, Nanjundaiah SM, Yu
H and Moudgil KD: Suppression of autoimmune arthritis by
Celastrus-derived Celastrol through mdoulation of pro-inflammatory
chemokines. Bioorg Med Chem. 20:5229–5234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Cao L, Xu LM, Cao FF, Peng B,
Zhang X, Shen YF, Uzan G and Zhang DH: Celastrol ameliorates EAE
induction by suppressing pathogenic T cell responses in the
peripheral and central nervous systems. J Neuroimmune Pharmacol.
10:506–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu J, Lee J, Salazar Hernandez MA,
Mazitschek R and Ozcan U: Treatment of obesity with celastrol.
Cell. 161:999–1011. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu F, Li C, Jin XP, Weng SX, Fan LL,
Zheng Z, Li WL, Wang F, Wang WF, Hu XF, et al: Celastrol may have
an anti-atherosclerosis effect in rabbit experimental carotid
atherosclerosis model. Int J Clin Exp Med. 7:1684–1691. 2014.
|
|
14
|
Kim JE, Lee MH, Nam DH, Song HK, Kang YS,
Lee JE, Kim HW, Cha JJ, Hyun YY, Han SY, et al: Celastrol, an NF-κB
inhibitor, improves insulin resistance and attenuates renal injury
in db/db mice. PLoS One. 8:e620682013. View Article : Google Scholar
|
|
15
|
Han LP, Li CJ, Sun B, Xie Y, Guan Y, Ma ZJ
and Chen LM: Protective effects of celastrol on diabetic liver
injury via TLR4/MyD88/NF-κB signaling pathway in type 2 diabetic
rats. J Diabetes Res. 2016:26412482016. View Article : Google Scholar
|
|
16
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: HepG2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
|
17
|
Gómez-Lechón MJ, Donato MT,
Martínez-Romero A, Jiménez N, Castell JV and O'Connor JE: A human
hepatocellular in vitro model to investigate steatosis. Chem Biol
Interact. 165:106–116. 2007. View Article : Google Scholar
|
|
18
|
Xu F, Li Z, Zheng X, Liu H, Liang H, Xu H,
Chen Z, Zeng K and Weng J: SIRT1 mediates the effect of GLP-1
receptor agonist exenatide on ameliorating hepatic steatosis.
Diabetes. 63:3637–3646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng S, Liang S, Liu Q, Deng Z, Zhang Y,
Du J, Zhang Y, Li S, Cheng B and Ling C: Diosgenin prevents
high-fat diet-induced rat non-alcoholic fatty liver disease through
the AMPK and LXR signaling pathways. Int J Mol Med. 41:1089–1095.
2018.
|
|
20
|
Schwartz DM and Wolins NE: A simple and
rapid method to assay triacylglycerol in cells and tissues. J Lipid
Res. 48:2514–2520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Takaki A, Kawai D and Yamamoto K:
Molecular mechanisms and new treatment strategies for non-alcoholic
steatohepatitis (NASH). Int J Mol Sci. 15:7352–7379. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Szabo G and Petrasek J: Inflammasome
activation and function in liver disease. Nat Rev Gastroenterol
Hepatol. 12:387–400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kesar V and Odin JA: Toll-like receptors
and liver disease. Liver Int. 34:184–196. 2014. View Article : Google Scholar
|
|
25
|
Bieghs V and Trautwein C: The innate
immune response during liver inflammation and metabolic disease.
Trends Immunol. 34:446–452. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu ZJ, Fan JG, Wang XP and Wang GL:
Upregulating expressions of hepatic lipopolysaccharide receptors in
nonalcoholic steato-hepatitic rats. Zhonghua Gan Zang Bing Za Zhi.
14:49–52. 2006.In Chinese. PubMed/NCBI
|
|
27
|
Rivera CA, Adegboyega P, van Rooijen N,
Tagalicud A, Allman M and Wallace M: Toll-like receptor-4 signaling
and Kupffer cells play pivotal roles in the pathogenesis of
non-alcoholic steato-hepatitis. J Hepatol. 47:571–579. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sharifnia T, Antoun J, Verriere TG, Suarez
G, Wattacheril J, Wilson KT, Peek RM Jr, Abumrad NN and Flynn CR:
Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest
Liver Physiol. 309:G270–G278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shen YF, Zhang X, Wang Y, Cao FF, Uzan G,
Peng B and Zhang DH: Celastrol targets IRAKs to block Toll-like
receptor 4-mediated nuclear factor-κB activation. J Integr Med.
14:203–208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mehal WZ: The inflammasome in liver injury
and non-alcoholic fatty liver disease. Dig Dis. 32:507–515. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang N, Wang H, Yao H, Wei Q, Mao XM,
Jiang T, Xiang J and Dila N: Expression and activity of the
TLR4/NF-κB signaling pathway in mouse intestine following
administration of a short-term high-fat diet. Exp Ther Med.
6:635–640. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arias-Loste MT, Iruzubieta P, Puente Á,
Ramos D, Santa Cruz C, Estébanez Á, Llerena S, Alonso-Martín C, San
Segundo D, Álvarez L, et al: Increased expression profile and
functionality of TLR6 in peripheral blood mononuclear cells and
hepatocytes of morbidly obese patients with non-alcoholic fatty
liver disease. Int J Mol Sci. 17:E18782016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miura K and Ohnishi H: Role of gut
microbiota and Toll-like receptors in nonalcoholic fatty liver
disease. World J Gastroenterol. 20:7381–7391. 2014. View Article : Google Scholar : PubMed/NCBI
|
